public traded as tsx nvn industry biotechnology fate merged successor akela pharma inc founded 1990 as stressgen biotechnologies defunct 2009 2009 headquarters san diego california united states key people gregory m. mckee number of employees 5 website www.nventacorp.com nventa biopharmaceuticals corporation was a canadian incorporated biopharmaceutical company headquartered in san diego california developing therapeutics for the treatment of viral infections and cancer focusing on diseases caused by human papillomavirus hpv . nventa is currently the only company applying heat shock protein hsp technology to target the over 20 million americans already infected with hpv . 2 3 previously headquartered in victoria british columbia canada 4 the company s common stock traded on the toronto stock exchange under the symbol nvn . contents 1 development programs 2 clinical progress 3 senior management 4 merger with akela pharma inc 5 references development programs edit the company s lead candidate hspe7 is a novel therapeutic vaccine intended for the treatment of hpv related diseases . hspe7 is derived from nventa s patented coval fusion platform that uses recombinant dna technology to covalently fuse heat shock proteins to target antigens thereby stimulating cellular immune system responses to specific diseases . nventa is developing hspe7 in combination with the toll like receptor 3 tlr3 agonist adjuvant poly iclc for multiple indications including cervical intraepithelial neoplasia also known as cervical dysplasia or cin genital warts cervical cancer and head and neck cancers . according to the annual information form for the year ending december 31 2009 provided on akela pharma s website scientific research funding has ceased for hspe7 . nventa is also developing two additional therapeutic vaccine programs based on its coval technology a hsp hbv hepatitis b fusion and prototypes of hsp fusion proteins with influenza antigens . in june 2008 nventa announced the development of a proprietary vaccine adjuvant poly ic poly arginine poly icr for use with both therapeutic and prophylactic vaccines . poly icr is a tlr3 agonist that when combined with a disease specific antigen can induce both cytotoxic t cell and antibody b cell immune responses against that antigen . as yet unpublished pre clinical data indicate that poly icr in combination with a tumor associated antigen increases antigen specific cd8 t cell levels while both inducing regression of tumors and preventing tumor growth in mouse models . 5 the company developed poly icr for both internal use and for external licensing opportunities . clinical progress edit nventa originally advanced hspe7 as a single agent therapy into multiple phase 2 clinical trials with positive results including trials in cervical dysplasia 6 and recurrent respiratory papillomatosis rrp . 7 these trials were initiated prior to the discovery that potency could be greatly enhanced by addition of a vaccine adjuvant . 8 nventa is currently developing hspe7 combined with the th1 directed adjuvant poly iclc . a phase 1b study is complete assessing safety and tolerability in 17 patients with cin . 9 senior management edit gregory m. mckee 10 11 president and chief executive officer peter emtage ph.d. 12 vice president research and development merger with akela pharma inc edit on march 27 2008 akela pharma inc. and nventa biopharmaceuticals corporation announced the execution of an arrangement agreement to combine the two companies by way of a plan of arrangement under the business corporations act . the transaction will be effected by an exchange of akela common shares for the outstanding shares of nventa on the basis of 0.0355 akela shares for each nventa share resulting in about 70 30 ownership split between akela and nventa shareholders respectively in the combined entity . the public company will retain akela s name will operate under akela s management and will continue to be listed on the toronto stock exchange under the ticker symbol akl . nventa noted that it would have the right to nominate two directors to the board of directors of akela . 13 on may 22 2009 akela and nventa announced the closing of the arrangement agreement to combine the two companies and that the transaction has been approved by the shareholders of nventa the british columbia supreme court and the toronto stock exchange . 14 references edit company profile for nventa biopharmaceuticals corp ca ; nvn . retrieved 2008 10 15 . could our own proteins be used to help us fight cancer . retrieved 2008 07 01 . genital hpv infection cdc fact sheet . fierce biotech nventa consolidates offices into san diego . retrieved 2007 05 31 . company press release nventa develops proprietary vaccine adjuvant june 18 2008 drugs.com nventa announces presentation of positive hspe7 data from nci sponsored clinical trial in cervical dysplasia . retrieved 2007 03 05 . neefe jr ; smith rj ; mcclay j ; van burik ja ; wiatrak bj ; arnold j ; berger b ; neefe jr 2005 . hspe7 treatment of pediatric recurrent respiratory papillomatosis final results of an open label trial . ann otol rhinol laryngol . 114 9 730 7 . pmid 16240938 . international hpv conference poster nventa presents hspe7 data at international hpv conference nventa press release november 5 2007 clinicaltrialsfeeds.org safety study to test the safety of hspe7 and poly iclc given in patients with cervical intraepithelial neoplasia . retrieved 2008 05 05 . nature biotechnology people business week executive profile business week executive profile http www.rttnews.com content canadiannews.aspx node b1 & id 895489 company press release akela and nventa announce closing of merger retrieved from https en.wikipedia.org w index.php title nventa biopharmaceuticals corporation & oldid 743675001 categories biotechnology companies of the united statesdefunct companies based in californiacompanies based in san diegocompanies established in 1990companies disestablished in 2009hidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 10 october 2016 at 17 35 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view